- Home
- MLNK vs PCRX Comparison
MLNK vs PCRX Comparison
Compare MLNK & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- PCRX
- Stock Information
- Founded
- MLNK 1998
- PCRX 2006
- Country
- MLNK United States
- PCRX United States
- Employees
- MLNK N/A
- PCRX N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- MLNK Technology
- PCRX Health Care
- Exchange
- MLNK Nasdaq
- PCRX Nasdaq
- Market Cap
- MLNK 1.3B
- PCRX 1.2B
- IPO Year
- MLNK 2021
- PCRX 2011
- Fundamental
- Price
- MLNK $17.12
- PCRX $23.22
- Analyst Decision
- MLNK Hold
- PCRX Buy
- Analyst Count
- MLNK 7
- PCRX 9
- Target Price
- MLNK $20.64
- PCRX $29.89
- AVG Volume (30 Days)
- MLNK 424.2K
- PCRX 560.0K
- Earning Date
- MLNK 08-07-2025
- PCRX 07-29-2025
- Dividend Yield
- MLNK N/A
- PCRX N/A
- EPS Growth
- MLNK N/A
- PCRX N/A
- EPS
- MLNK N/A
- PCRX N/A
- Revenue
- MLNK $319,970,000.00
- PCRX $702,772,000.00
- Revenue This Year
- MLNK $6.24
- PCRX $7.54
- Revenue Next Year
- MLNK $5.85
- PCRX $10.78
- P/E Ratio
- MLNK N/A
- PCRX N/A
- Revenue Growth
- MLNK 5.15
- PCRX 3.08
- 52 Week Low
- MLNK $15.49
- PCRX $11.16
- 52 Week High
- MLNK $25.33
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- MLNK 56.16
- PCRX 34.52
- Support Level
- MLNK $16.09
- PCRX $22.82
- Resistance Level
- MLNK $17.32
- PCRX $24.36
- Average True Range (ATR)
- MLNK 0.57
- PCRX 0.69
- MACD
- MLNK 0.09
- PCRX -0.12
- Stochastic Oscillator
- MLNK 89.17
- PCRX 12.39
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.